Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022
Posted: November 5, 2022 at 1:42 am
New Data Detail Efficacy of HDAC6 Inhibition Compared to Empagliflozin in Model of Heart Failure with Preserved Ejection Fraction New Data Detail Efficacy of HDAC6 Inhibition Compared to Empagliflozin in Model of Heart Failure with Preserved Ejection Fraction
View post:
Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022
Recommendation and review posted by G. Smith
